Director Steven H. Collis bought 3,000 shares of Elevance Health, Inc. (NYSE: ELV) on March 5, 2026, at a per-share price of $289.84, bringing the total transaction value to $869,519. After the purchase, Collis directly holds 3,639 shares of the company.
The timing of the purchase coincides with Elevance trading close to its 52-week low of $273.71. Analysis from InvestingPro cited in coverage indicates that the company appears materially undervalued relative to its Fair Value.
InvestingPro also provides a dedicated Pro Research Report on ELV as part of its coverage universe of more than 1,400 U.S. equities, offering additional research and analysis to investors seeking deeper information.
Regulatory developments
Separately, Elevance Health has been notified by the Centers for Medicare & Medicaid Services (CMS) of an intent to impose sanctions on the company’s Medicare Advantage-Prescription Drug plans. Those planned sanctions are scheduled to take effect on March 31 and would suspend the enrollment of new Medicare beneficiaries and limit certain communications. The notification specifies that current members’ plans would remain unaffected by the measures.
Market participants continue to assess the implications of those actions. TD Cowen has reiterated a Buy rating on Elevance Health and set a price target of $400, noting attention remains on possible monetary remediation tied to the situation.
Management changes at Carelon
Elevance also announced an internal management reorganization that expands the role of Executive Vice President and Chief Financial Officer Mark Kaye to include oversight of the Carelon division. In the wake of that restructuring, Peter Haytaian, president of the Carelon services division, is reportedly planning to depart the company, according to Bloomberg. The Carelon unit— which encompasses pharmacy benefits—has been identified as a rapidly growing segment within Elevance’s business mix.
Unrelated resource-sector update
In a separate development included in the same coverage, Elevra Lithium Limited signed a non-binding Memorandum of Understanding with Mangrove Lithium concerning supply of spodumene concentrate from operations in Quebec. Under the terms outlined, the agreement could result in Elevra supplying up to 144,000 tonnes per year over five years, beginning in 2028. The memorandum is non-binding, indicating the arrangement is not yet contractually firm.
The sequence of insider buying, regulatory notices, management realignment and third-party resource agreements outlines a multifaceted set of developments for investors monitoring Elevance Health and related market activity.